| scholarly article | Q13442814 |
| P50 | author | Kenneth C. Kalunian | Q111604424 |
| Mary Anne Dooley | Q111604480 | ||
| Ian Bruce | Q30348366 | ||
| Dafna D. Gladman | Q37605821 | ||
| David A. Isenberg | Q42326409 | ||
| Sang-Cheol Bae | Q50911059 | ||
| Caroline Gordon | Q58049734 | ||
| Graciela S Alarcón | Q67485107 | ||
| Michelle A. Petri | Q67485110 | ||
| Rosalind Ramsey-Goldman | Q67485111 | ||
| Joan T Merrill | Q67485131 | ||
| Munther A. Khamashta | Q73418907 | ||
| Sasha Bernatsky | Q87985660 | ||
| Cynthia Aranow | Q91409089 | ||
| Ellen M Ginzler | Q91640182 | ||
| Susan Manzi | Q111603941 | ||
| P2093 | author name string | A Clarke | |
| A Rahman | |||
| D J Wallace | |||
| O Nived | |||
| J G Hanly | |||
| P R Fortin | |||
| K Steinsson | |||
| M Ramos | |||
| A Zoma | |||
| G Sturfelt | |||
| J Sanchez-Guerrero | |||
| M B Urowitz | |||
| P Maddison | |||
| R F Van Vollenhoven | |||
| T Stoll | |||
| Systemic Lupus International Collaborating Clinics | |||
| D Ibañez | |||
| P2860 | cites work | Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 |
| Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 | ||
| Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort | Q31122937 | ||
| Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort | Q31145074 | ||
| Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus | Q38454380 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. | Q43552335 | ||
| Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. | Q43587941 | ||
| The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 | ||
| Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. | Q50119393 | ||
| Risk factors for coronary artery disease in patients with systemic lupus erythematosus | Q67586359 | ||
| Morbidity in systemic lupus erythematosus | Q69148719 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus | Q73343774 | ||
| The Systemic Lupus International Collaborating Clinics Group--origins and outcomes | Q74012759 | ||
| Systemic lupus erythematosus disease activity index 2000 | Q77624632 | ||
| Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 | ||
| Premature atherosclerosis in systemic lupus erythematosus | Q81794167 | ||
| P433 | issue | 6 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 881-887 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Arthritis Care and Research | Q15754720 |
| P1476 | title | Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus | |
| P478 | volume | 62 |
| Q35086343 | 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort |
| Q85173072 | Atherosclerosis in systemic lupus: The role of antiphospholipid antibodies needs strict diagnostic criteria to be evaluated. Comment on the article by Urowitz et al |
| Q38365624 | Atherosclerotic vascular disease in the autoimmune rheumatologic patient |
| Q35868721 | Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis |
| Q47208789 | Blood pressure control over time in childhood-onset systemic lupus erythematous |
| Q88105277 | C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population |
| Q64114060 | Cardiac phenotype in mouse models of systemic autoimmunity |
| Q36153524 | Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry |
| Q37330468 | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. |
| Q43885994 | Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q36680400 | Cardiovascular risk factors in systemic lupus erythematosus |
| Q47556201 | Cerebrovascular Events in Systemic Lupus Erythematosus |
| Q38223293 | Childhood onset systemic lupus erythematosus: how is it different from adult SLE? |
| Q64089219 | Critical limb ischemia in a patient with systemic lupus erythematosus: a case report |
| Q38186995 | Diagnosis and management of neuropsychiatric SLE. |
| Q54968810 | Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction. |
| Q54263409 | Disease characteristics and causes of early and late death in a group of Croatian patients with systemic lupus erythematosus deceased over a 10-year period. |
| Q38654271 | Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus? |
| Q36139802 | Effect of Systemic Lupus Erythematosus on the Risk of Incident Respiratory Failure: A National Cohort Study |
| Q37883018 | Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. |
| Q43427893 | Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus |
| Q83115423 | Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus |
| Q35162593 | IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study |
| Q35450156 | Imaging assessment of cardiovascular disease in systemic lupus erythematosus |
| Q37715144 | Impaired arterial stiffness in systemic lupus ertythematosus - correlations with inflammation markers |
| Q39405417 | Incidence and risk of heart failure in systemic lupus erythematosus |
| Q50503818 | Increased risk of subarachnoid hemorrhage in patients with systemic lupus erythematosus: a nationwide population-based study. |
| Q38889941 | Maternal-placental syndrome and future risk of accelerated cardiovascular events in Parous Swedish women with systemic lupus erythematosus - a population-based retrospective cohort study with time-to-event analysis |
| Q33425745 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients |
| Q24603979 | Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis |
| Q55267080 | Neurological Disease in Lupus: Toward a Personalized Medicine Approach. |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q39053063 | Peripheral arterial disease in patients with systemic lupus erythematosus: a prospective controlled study |
| Q53694045 | Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus. |
| Q34705015 | Presentation of systemic lupus erythematosus (SLE) in emergency department: a case report |
| Q50637234 | Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts. |
| Q36299359 | Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study |
| Q33922922 | Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. |
| Q37294162 | Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases |
| Q38844621 | Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment |
| Q43468721 | Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center |
| Q34630261 | Systemic lupus erythematosus and cardiac risk factors: medical record documentation and patient adherence |
| Q35947491 | Systemic lupus erythematosus in children and adolescents |
| Q37957814 | The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today |
| Q28486062 | The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus |
| Q39283399 | The evolving concept of SLE comorbidities. |
| Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
| Q38149851 | Transient ischemic attack and stroke in systemic lupus erythematosus |
| Q38844782 | Update on cardiovascular disease in lupus |
| Q33818710 | Use of atorvastatin in systemic lupus erythematosus in children and adolescents |
| Q38011226 | Utilizing registries in systemic lupus erythematosus clinical research |
| Q21285155 | Vascular disease in systemic lupus erythematosus |
| Q38591752 | Why are kids with lupus at an increased risk of cardiovascular disease? |
| Q52887081 | [Neurological manifestations in connective tissue disease]. |
Search more.